”Investigators are scaling the dosing according to age. In the Moderna trial, some children 6 to 11 years old are starting at adult doses or given less; younger children are starting with lower doses. Pfizer is starting children with a third of a dose and scaling up, and then basing younger children’s doses on older children’s responses. The Pfizer vaccine approved last week for 12-to-15-year-olds is the same dose as for adults, but sometimes lower doses are equally effective in children because their immune systems may be more responsive.“
Phase 1 is the open-label dose-finding portion of the study to evaluate safety, tolerability, and immunogenicity of BNT162b2 on a 2-dose (separated by approximately 21 days) schedule in up to 3 age groups (participants ≥5 to <12 years, ≥2 to <5 years, and ≥6 months to <2 years of age). Dose finding is being initiated in this study in participants ≥5 to <12 years of age based on the acceptable blinded safety assessment of the 30-μg dose in 12- to 15-year-olds in the C4591001 study.
The purpose of Phase 1 is to identify preferred dose level(s) of BNT162b2 from up to 3 different dose levels in each age group.
查了一下S protein的檢驗 貌似結果報告只是說positive or negative, 沒有給數量啊
简单讲，对目前最令人担心的印度变异，打一针的保护率是33%，打两针的保护率是88%，就问你要选哪个？
https://bbs.wenxuecity.com/health/977813.html
航空公司按体重售票，登机前过磅复查，超重部分按手提行李计价。
Children enroll in Pfizer and Moderna trials for those under 12 - The Washington Post
”Investigators are scaling the dosing according to age. In the Moderna trial, some children 6 to 11 years old are starting at adult doses or given less; younger children are starting with lower doses. Pfizer is starting children with a third of a dose and scaling up, and then basing younger children’s doses on older children’s responses. The Pfizer vaccine approved last week for 12-to-15-year-olds is the same dose as for adults, but sometimes lower doses are equally effective in children because their immune systems may be more responsive.“
5-11 岁
https://clinicaltrials.gov/ct2/show/NCT04816643
，
Phase 1 is the open-label dose-finding portion of the study to evaluate safety, tolerability, and immunogenicity of BNT162b2 on a 2-dose (separated by approximately 21 days) schedule in up to 3 age groups (participants ≥5 to <12 years, ≥2 to <5 years, and ≥6 months to <2 years of age). Dose finding is being initiated in this study in participants ≥5 to <12 years of age based on the acceptable blinded safety assessment of the 30-μg dose in 12- to 15-year-olds in the C4591001 study.
The purpose of Phase 1 is to identify preferred dose level(s) of BNT162b2 from up to 3 different dose levels in each age group.
12-15岁，与成年组混在一起
https://clinicaltrials.gov/ct2/show/NCT04368728
在决定剂量的一期临试中，没有包括18岁以下的。12-15岁组，从二期开始加入。这就是为啥俺说厂家“偷工”。
In 3 age groups (Phase 1: 18 to 55 years of age, 65 to 85 years of age; Phase 2/3: ≥12 years of age [stratified as 12-15, 16-55 or >55 years of age]).